Next Article in Journal
Best-Evidence for the Rehabilitation of Chronic Pain Part 1: Pediatric Pain
Next Article in Special Issue
Regulated hAAT Expression from a Novel rAAV Vector and Its Application in the Prevention of Type 1 Diabetes
Previous Article in Journal
Does the Implementation of a Quality Improvement Care Bundle Reduce the Incidence of Acute Kidney Injury in Patients Undergoing Emergency Laparotomy?
Previous Article in Special Issue
Immunoproteomic Lessons for Human Respiratory Syncytial Virus Vaccine Design
 
 
Article
Peer-Review Record

Peptide Antagonists for P-selectin Discriminate between Sulfatide-Dependent Platelet Aggregation and PSGL-1-Mediated Cell Adhesion

J. Clin. Med. 2019, 8(8), 1266; https://doi.org/10.3390/jcm8081266
by Suzanne J.A. Korporaal 1,2,3,†, Tom J.M. Molenaar 1,†, Bianca C.H. Lutters 1,†, Illiana Meurs 1, Sandra Drost-Verhoef 2, Johan Kuiper 1, Theo J.C. van Berkel 1 and Erik A.L. Biessen 4,5,*
Reviewer 1: Anonymous
Reviewer 2: Anonymous
J. Clin. Med. 2019, 8(8), 1266; https://doi.org/10.3390/jcm8081266
Submission received: 18 July 2019 / Revised: 8 August 2019 / Accepted: 16 August 2019 / Published: 20 August 2019

Round 1

Reviewer 1 Report

In the present study, authors reported the design of specific peptide antagonists for P-selectin and showed that peptides carrying an EWVDV minimal motif interacted with P-selectin in close proximity to the PSGL-1 binding site on P-selectin, which was proposed to overlap with that of sulfatides. The present study showed that P-selectin binding to sulfatide-laden liposomes requires a threshold sulfatide density, that activated platelets express clusters of surface-exposed sulfatides, and that the binding profile of P-selectin to sulfatides differs from that to PSGL-1. Authors’ experiments showed that elongated but not truncated EWVDV peptide antagonists inhibit sulfatide binding to P-selectin as well as platelet aggregation. However, the following issues remain to be clarified before acceptance.

Major comment:

1.For human platelet experiments, it is described “Freshly drawn venous blood from healthy volunteers was collected with informed consent into 0.1 volume 130 mmol/L trisodium citrate. The donors were free of medication for at least two weeks prior to blood collection.” Was it done with written consent form? Authors need to provide the IRB number.

2.It needs to be described whether human subjects fasted overnight before the blood samples were collected. There are no information on the number of platelets donors in the studyWhat is the interval from time of blood drawing to final test?

3.Authors needs to provide the Animal care number.

4.Does peptide antagonists (e.g. EWVKV, EWVDV, DVEWVDVS, and CDVEWVDVSC) have any cytotoxic effects in platelets?

Author Response

Please see attachment.

Author Response File: Author Response.pdf

Reviewer 2 Report

The manuscript "Peptide antagonists for P-selectin discriminate between sulfatide-dependent platelet aggregation and PSGL-1-mediated cell adhesion", written by Korporaal et al. describes a process, where P-selectin-mediated platelet aggregation on a collagen-coated surface depends on present sulfatides. The manuscript is well and carefully written, and the theme is sound and it is worth to pursuit. I have only a few very minor comments:

1. Quality of the figure 3 should be improved. The labels are difficult to read.

2. The figure 3E should be divided into two separate figures to incrase readability. 

Author Response

Please see the attachment.

Author Response File: Author Response.pdf

Back to TopTop